精神科研究中安慰剂效应:西酞普兰与艾司西酞普兰随机对照试验的系统综述与荟萃分析
安慰剂效应量大(效应量1.01,95%CI 0.93-1.10),异质性显著(I2=99.61%);创伤后应激障碍与抑郁障碍安慰剂效应最高(分别为1.14和1.02),强迫症最低(0.62,P<0.01)。药物效应量1.43,在不同精神障碍间无显著差异(P=0.61)。
要点
- 安慰剂效应在精神科试验中量大且异质性高,不同疾病间差异显著。
- 创伤后应激障碍与抑郁障碍安慰剂效应最高,强迫症最低,特定恐惧症在焦虑障碍亚类中最低(0.23)。
- 更多研究组、更年轻平均年龄、临床医生评定结局、多中心研究和意向性治疗数据与更大安慰剂效应相关。
核心结论
- 精神科安慰剂治疗反应量大且异质性显著,受研究设计与人口学因素影响。
- 不同精神障碍间安慰剂效应存在显著差异,而药物效应量在不同障碍间无显著差异。
研究设计与样本
- PROSPERO注册的系统综述与荟萃分析,遵循PRISMA指南。
- 纳入至少含一个安慰剂组和一个药物组(西酞普兰或艾司西酞普兰)的随机对照试验,覆盖抑郁、焦虑、强迫症和创伤后应激障碍四类精神障碍。
主要发现
- 安慰剂效应量为1.01(95%CI 0.93-1.10),异质性I2为99.61%。
- 创伤后应激障碍安慰剂效应量1.14,抑郁障碍1.02,强迫症0.62(P<0.01),焦虑障碍0.86。
- 特定恐惧症安慰剂效应量0.23(P<0.01),为焦虑障碍亚类中最低。
- 药物效应量1.43(I2=99.76%),在不同精神障碍间无显著差异(P=0.61)。
- 研究组更多(b=0.181,P<0.01)和平均年龄更小(b=-0.010,P<0.01)与更大安慰剂效应相关;临床医生评定结局 vs 患者自报(1.07 vs 0.76,P<0.01)、多中心研究(P<0.01)和意向性治疗数据(1.08 vs 0.86,P=0.01)与更大安慰剂效应相关。
关键数值与推荐
- 安慰剂效应量1.01(95%CI 0.93-1.10),I2=99.61%。
- 创伤后应激障碍1.14、抑郁障碍1.02、焦虑障碍0.86、强迫症0.62(P<0.01)、特定恐惧症0.23(P<0.01)。
- 药物效应量1.43,I2=99.76%,不同障碍间P=0.61。
- 更多研究组b=0.181(P<0.01),平均年龄b=-0.010(P<0.01)。
- 临床医生评定 vs 患者自报1.07 vs 0.76(P<0.01);意向性治疗 vs 非意向性治疗1.08 vs 0.86(P=0.01)。
临床怎么用
- 解读精神科随机对照试验结果时需考虑疾病特异性安慰剂效应及研究设计因素的影响。
- 临床试验设计应关注研究组数量、结局评定方式(临床医生评定 vs 患者自报)和统计分析人群对安慰剂效应估计的影响。
- 临床转化时需注意安慰剂反应的异质性,避免将试验中的效应量直接外推至日常实践。
局限性
- 研究仅纳入西酞普兰和艾司西酞普兰试验,结论向其他药物外推受限。
- 未报告发表偏倚评估、纳入研究质量评价等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Placebos have historically been used as comparative tools in randomised controlled trials (RCTs), but their therapeutic effect, particularly in psychiatric conditions, warrant a more detailed exploration to improve research design and clinical practice. AIMS: This systematic review and meta-analysis examines the factors influencing placebo treatment effects across major psychiatric disorders, including depression, anxiety disorders, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). METHOD: This PROSPERO registered systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify RCTs with at least one placebo and one medication arm (citalopram or escitalopram), across four major groups of psychiatric conditions. Data extraction focused on study characteristics, methodology, target condition, participant demographics and outcome measurements. Cohen's d effect sizes for placebo and medication groups were calculated, with random-effects model meta-analyses performed to assess heterogeneity and their correlates. RESULTS: The review included 80 studies with 312 outcome measures, involving 19 776 participants (7 to 91 years old). A large placebo response was observed (effect size: 1.01; 95% CI: 0.93-1.10) with significant heterogeneity (I2: 99.61%). Significant differences in placebo responses were noted across clinical conditions, independent of the medication type. PTSD and depressive disorders exhibited the highest placebo effect size (1.14 and 1.02, respectively), whereas OCD showed the lowest (effect size: 0.62, P < 0.01). Anxiety disorders displayed a moderately large placebo effect size (0.86), with significant variability among anxiety disorder subclasses, specifically noting the lowest placebo effect size in specific phobia (0.23, P < 0.01). The medication effect size (1.43) also demonstrated considerable heterogeneity (I2: 99.76%) but was not significantly different across psychiatric conditions (P = 0.61). Placebo response magnitude was larger in studies with more study arms (b: 0.181, P < 0.01) and younger mean age of the participant (b: -0.010, P < 0.01). Moreover, clinician-rated outcomes versus patient self-reports (effect size: 1.07 v. 0.76, P < 0.01), multicentre studies (p < 0.01) and using intention-to-treat data (effect size: 1.08 v. 0.86, P = 0.01) were associated with larger placebo effect size. CONCLUSIONS: This study used a unique approach to examine placebo responses from the same interventions across multiple major psychiatric disorders. We found substantial placebo responses across psychiatric conditions and significant heterogeneity, influenced by a range of study-related and demographic factors. The findings underscore the complexity of placebo responses and highlight the importance of considering these variances in both research design and clinical translation.
引用
- Ahmadzad-Asl M, Jabbarinejad R, Shekouh D, et al. Beyond control in psychiatric research: systematic review and meta-analysis of placebo treatment responses across major psychiatric conditions in citalopram and escitalopram RCTs. Br J Psychiatry. 2026. PMID: 42639721. doi:10.1192/bjp.2026.10665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。